State Street’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-4,097,885
| Closed | -$296M | – | 4329 |
|
|
2025
Q4 | $296M | Sell |
4,097,885
-790,747
| -16% | -$51.1M | 0.01% | 756 |
|
|
2025
Q3 | $213M | Buy |
4,888,632
+687,123
| +16% | +$27.8M | 0.01% | 901 |
|
|
2025
Q2 | $119M | Sell |
4,201,509
-119,851
| -3% | -$3.57M | ﹤0.01% | 1209 |
|
|
2025
Q1 | $128M | Sell |
4,321,360
-280,831
| -6% | -$8.75M | 0.01% | 1145 |
|
|
2024
Q4 | $134M | Sell |
4,602,191
-103,915
| -2% | -$4.34M | 0.01% | 1170 |
|
|
2024
Q3 | $216M | Buy |
4,706,106
+1,386,087
| +42% | +$60.2M | 0.01% | 875 |
|
|
2024
Q2 | $136M | Sell |
3,320,019
-141,803
| -4% | -$4.07M | 0.01% | 1083 |
|
|
2024
Q1 | $88.3M | Buy |
3,461,822
+23,494
| +0.7% | +$368K | ﹤0.01% | 1393 |
|
|
2023
Q4 | $31.1M | Sell |
3,438,328
-721,964
| -17% | -$4.83M | ﹤0.01% | 1956 |
|
|
2023
Q3 | $26.5M | Sell |
4,160,292
-2,029,301
| -33% | -$17.5M | ﹤0.01% | 2002 |
|
|
2023
Q2 | $68.6M | Buy |
6,189,593
+1,812,533
| +41% | +$22.7M | ﹤0.01% | 1468 |
|
|
2023
Q1 | $67.2M | Buy |
4,377,060
+806,933
| +23% | +$17.8M | ﹤0.01% | 1446 |
|
|
2022
Q4 | $79.2M | Buy |
3,570,127
+1,809,796
| +103% | +$27M | ﹤0.01% | 1331 |
|
|
2022
Q3 | $28.7M | Sell |
1,760,331
-77,344
| -4% | -$1.48M | ﹤0.01% | 1969 |
|
|
2022
Q2 | $26.7M | Buy |
1,837,675
+195,808
| +12% | +$2.91M | ﹤0.01% | 2045 |
|
|
2022
Q1 | $30.3M | Buy |
1,641,867
+244,464
| +17% | +$4.15M | ﹤0.01% | 2096 |
|
|
2021
Q4 | $33.2M | Sell |
1,397,403
-31,601
| -2% | -$755K | ﹤0.01% | 2104 |
|
|
2021
Q3 | $35.2M | Buy |
1,429,004
+85,886
| +6% | +$1.87M | ﹤0.01% | 2064 |
|
|
2021
Q2 | $33.2M | Sell |
1,343,118
-5,555
| -0.4% | -$129K | ﹤0.01% | 2148 |
|
|
2021
Q1 | $29.4M | Buy |
1,348,673
+667,679
| +98% | +$16.3M | ﹤0.01% | 2110 |
|
|
2020
Q4 | $17.4M | Buy |
680,994
+436,557
| +179% | +$12.7M | ﹤0.01% | 2321 |
|
|
2020
Q3 | $6.88M | Buy |
+244,437
| New | +$7.06M | ﹤0.01% | 2642 |
|
Other funds holding RNAM
State Street's RNAM Position: Q1 2026 in Review
State Street sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 4,097,885 shares — an estimated $296M sold.
State Street first reported a position in RNAM in Q3 2020 and held it in 22 quarters. The position peaked at $296M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- State Street reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- State Street sold 4,097,885 Avidity Biosciences shares in Q1 2026, an estimated $296M.
- State Street first reported a position in Avidity Biosciences in Q3 2020 and held it in 22 quarters.
- State Street's Avidity Biosciences position peaked at $296M in Q4 2025.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.